This invention the pirazoropirimijinon derivative (the 5 [the 2 propyl oxy 5 (1 methyl 2 pirorijiniruechiruamidosuruhoniru) phenyl] 1 methyl - propyl 1,6 jihidoro 7H pirazoro (4,3 d) pyrimidine 7 on) regards prevention and remedy of the liver disease which it includes as the active ingredient the medicine composition. As for the pirazoropirimijinon derivative of this invention, the collagen synthetic depression effect in the liver star cell is excellent, it decreases the resistance and portal vein pressure inside the liver simultaneously and in order to increase the blood influx inside the liver which minds the portal vein, the hepatic cirrhosis due to the advance of liver tissue conversion and liver tissue conversion, portal vein pressure the Shank symptom and it can use for the usefulness in the preventive of the various complications which are induced from those and remedy medicine. In addition, as for the pirazoropirimijinon derivative of this invention, because human body inside half-life is long, it is possible, to decrease the frequency of taking, it is possible to raise the compliance in the chronic liver diseased patient substantially.本発明は、ピラゾロピリミジノン誘導体(5-[2-プロピルオキシ-5-(1-メチル-2-ピロリジニルエチルアミドスルホニル)フェニル]-1-メチル-プロピル-1,6-ジヒドロ-7H-ピラゾロ(4,3-d)ピリミジン-7-オン)を有効成分として含む肝疾患の予防及び治療用医薬組成物に関する。本発明のピラゾロピリミジノン誘導体は、肝星細胞でのコラーゲン合成抑制効果が優秀であり、同時に肝内抵抗および門脈圧を低下させて門脈を介した肝臓内血液流入を増加させるため、肝線維化、肝線維化の進行による肝硬変、門脈圧亢進症及びそれらから誘発される多様な合併症の予防及び治療剤に有用に使用することができる。また、本発明のピラゾロピリミジノン誘導体は、人体内半減期が長いため服用回数を減らすことができ、慢性肝疾患患者におけるコンプライアンスを大幅に高めることができる。
